肠源性内毒素刺激内皮细胞分泌凝血因子VIII:对肝硬化高凝状态的启示
横断面研究比较61例肝硬化患者与61例匹配对照的凝血因子VIII、血管性血友病因子(vWf)、脂多糖(LPS)及大肠埃希菌DNA阳性率,发现患者上述指标均升高,血清LPS与因子VIII独立相关;体外研究显示LPS通过Toll样受体4刺激人脐静脉内皮细胞释放因子VIII和vWf。
要点
- 肝硬化患者血清LPS、因子VIII、vWf及大肠埃希菌DNA阳性率均高于匹配对照。
- 血清LPS与因子VIII(r=0.80)及vWf(r=0.63)显著相关,仅LPS独立预测因子VIII水平。
- LPS经Toll样受体4刺激内皮细胞释放因子VIII和vWf,可能参与肝硬化高凝状态。
核心结论
- 研究首次提供证据表明源自肠道菌群的LPS通过刺激内皮细胞释放而增加因子VIII的系统水平。
研究设计与样本
- 横断面研究纳入肝硬化患者61例与匹配对照61例,比较血液因子VIII、vWf、LPS水平及大肠埃希菌DNA阳性率。
- 体外研究用人脐静脉内皮细胞(HUVEC)观察LPS是否刺激因子VIII分泌。
主要发现
- 肝硬化患者血清LPS为55.8(42.2-79.9)pg/ml vs 对照23.0(7.0-34.0)pg/ml,p<0.001。
- 肝硬化患者因子VIII为172.0(130.0-278.0)U/dl vs 对照39.0(26.0-47.0)U/dl,p<0.0001。
- 肝硬化患者vWf为265.0(185.0-366.0)U/dl vs 对照57.0(48.0-65.0)U/dl,p<0.001。
- 肝硬化患者大肠埃希菌DNA阳性率为88% vs 对照3%,p<0.001,n=34。
- 血清LPS与因子VIII(r=0.80,p<0.001)及vWf(r=0.63,p<0.001)显著相关,仅LPS独立预测因子VIII水平(beta系数=0.70,p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with cirrhosis display enhanced blood levels of factor VIII, which may result in harmful activation of the clotting system; however, the underlying mechanism is unknown. METHODS: We performed a cross-sectional study in patients with cirrhosis (n=61) and matched controls (n=61) comparing blood levels of factor VIII, von Willebrand factor (vWf), lipopolysaccharide (LPS) and positivity for Escherichia coli DNA. Furthermore, we performed an in vitro study to investigate if LPS, in a concentration range similar to that found in the peripheral circulation of cirrhotic patients, was able to elicit factor VIII secretion from human umbilical vein endothelial cells (HUVEC). RESULTS: Patients with cirrhosis displayed higher serum levels of LPS (55.8 [42.2-79.9] vs. 23.0 [7.0-34.0]pg/ml, p<0.001), factor VIII (172.0 [130.0-278.0] vs. 39.0 [26.0-47.0]U/dl, p<0.0001), vWf (265.0 [185.0-366.0] vs. 57.0 [48.0-65.0]U/dl, p<0.001) and positivity for Escherichia coli DNA (88% vs. 3%, p<0.001, n=34) compared to controls. Serum LPS correlated significantly with factor VIII (r=0.80, p<0.001) and vWf (r=0.63, p<0.001). Only LPS (beta-coefficient=0.70, p<0.0001) independently predicted factor VIII levels. The in vitro study showed that LPS provoked factor VIII and vWf release from HUVEC via formation and secretion of Weibel-Palade bodies, a phenomenon blunted by pre-treating HUVEC with an inhibitor of Toll-like receptor 4. CONCLUSIONS: The study provides the first evidence that LPS derived from gut microbiota increases the systemic levels of factor VIII via stimulating its release by endothelial cells. Lay summary: Cirrhosis is associated with thrombosis in portal and systemic circulation. Enhanced levels of factor VIII have been suggested to play a role but the underlying mechanism is still unclear. Here we show that patients with cirrhosis display a concomitant increase of factor VIII and lipopolysaccharide (LPS) from Escherichia coli and suggest that LPS contributes to the release of factor VIII from endothelial cells.
引用
- Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol. 2017. PMID: 28716745. doi:10.1016/j.jhep.2017.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。